P500 Effectiveness and safety in Crohn's disease patients who were treated with CT-P13

Choe, Yeon Hyeon; Lee, S.-H.; Park, D.I.; Lee, J.H.; Kim, H.J.; Kim, Y.-H.; Choi, Chang Hwan; Eun, Chang Soo; Lee, S.J.

doi:10.1093/ecco-jcc/jjx002.624

Journal of Crohn's and Colitis

2017

DOI: 10.1093/ecco-jcc/jjx002.624

|View full text |Cite

P500 Effectiveness and safety in Crohn's disease patients who were treated with CT-P13

Yeon Hyeon Choe

S.-H. Lee²,

D.I. Park

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Comparative effectiveness of the biosimilar CT-P13

Yoo

2017

J. Comp. Eff. Res.

View full text Add to dashboard Cite

The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries. Despite approval for clinical use, some knowledge gaps still limit the widespread and pertinent use of biosimilar CT-P13. One of the most important factors for proper utilization of CT-P13 for the treatment of immune-mediated inflammatory diseases is confidence in CT-P13, which could be enhanced by scientific evidence supporting the biosimilarity of CT-P13. Overall, five randomized controlled studies have been performed. For the other extrapolated indications, many observational induction and switching studies also support the utility of CT-P13 in the treatment of inflammatory diseases. Here, we review profiles of CT-P13 including physicochemical properties, clinical efficacy and safety data in all indications and current status.

show abstract

Comparative effectiveness of the biosimilar CT-P13

Yoo

2017

J. Comp. Eff. Res.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P500 Effectiveness and safety in Crohn's disease patients who were treated with CT-P13

Cited by 1 publication

References 0 publications

Comparative effectiveness of the biosimilar CT-P13

Comparative effectiveness of the biosimilar CT-P13

Contact Info

Product

Resources

About